Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Recommendation of “Moderate Buy” from Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $49.60.

A number of research analysts have recently commented on the company. Evercore assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective on the stock. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Jefferies Financial Group upped their target price on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. The Goldman Sachs Group started coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Trading Up 3.7%

Shares of COAG opened at $51.74 on Wednesday. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $53.61. The business’s fifty day simple moving average is $37.46. The firm has a market cap of $2.42 billion and a price-to-earnings ratio of -2.16.

Hemab Therapeutics (NASDAQ:COAG) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.17). Research analysts anticipate that Hemab Therapeutics will post -2.89 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was purchased at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the transaction, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 72,467 shares of company stock valued at $1,809,595.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.